• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan.

作者信息

Matsumoto Naoki, Abe Hiroto, Kawasaki Ryohei, Tashiro Yoshihito, Noguchi-Sasaki Mariko, Harada Suguru, Yoneyama Koichiro, Niino Tomomi, Soeda Tetsuhiro, Yoshimura Yasushi

机构信息

Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan.

Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan.

出版信息

TH Open. 2023 Aug 28;7(3):e241-e243. doi: 10.1055/a-2122-7887. eCollection 2023 Jul.

DOI:10.1055/a-2122-7887
PMID:37645671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10462426/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ac9/10462426/b5dc0027a7ae/10-1055-a-2122-7887-i23030009-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ac9/10462426/b5dc0027a7ae/10-1055-a-2122-7887-i23030009-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ac9/10462426/b5dc0027a7ae/10-1055-a-2122-7887-i23030009-1.jpg

相似文献

1
Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan.利用在日本开展的艾美赛珠单抗临床研究中获得的储存样本对艾美赛珠单抗抗体进行表征分析。
TH Open. 2023 Aug 28;7(3):e241-e243. doi: 10.1055/a-2122-7887. eCollection 2023 Jul.
2
Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor.对一名患有A型血友病且产生抑制剂的患者体内中和性抗emicizumab抗体的特征分析。
J Thromb Haemost. 2021 Mar;19(3):711-718. doi: 10.1111/jth.15226. Epub 2021 Feb 1.
3
[Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].[依米珠单抗，一种模拟凝血因子 VIII 的双特异性抗体：一种针对伴有抑制剂的甲型血友病的新型替代疗法]
Rinsho Ketsueki. 2019;60(5):475-479. doi: 10.11406/rinketsu.60.475.
4
Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.利用抗独特型单克隆抗体在存在依库珠单抗的情况下常规检测因子 VIII 活性和抑制剂滴度。
J Thromb Haemost. 2018 Jul;16(7):1383-1390. doi: 10.1111/jth.14135. Epub 2018 May 27.
5
Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.对血友病 A 患者血浆样本进行抗emicizumab 抗体降低药物疗效的详细分析。
J Thromb Haemost. 2021 Dec;19(12):2938-2946. doi: 10.1111/jth.15506. Epub 2021 Sep 28.
6
Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.针对emicizumab的抗独特型单克隆抗体能够在emicizumab存在的情况下，无论检测基础如何，都能实现准确的促凝血和抗凝血检测。
Haemophilia. 2023 Jan;29(1):329-335. doi: 10.1111/hae.14662. Epub 2022 Sep 22.
7
An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.一种抗因子IXa/因子X双特异性抗体——emicizumab，可改善获得性血友病A患者血浆的体外凝血潜能。
J Thromb Haemost. 2020 Apr;18(4):825-833. doi: 10.1111/jth.14746. Epub 2020 Feb 26.
8
Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.评估同时使用依美珠单抗和旁路制剂治疗伴有抑制物的血友病 A 患者的整体凝血功能（UNEBI 研究）：多中心开放标签非随机临床试验。
BMJ Open. 2022 Feb 17;12(2):e056922. doi: 10.1136/bmjopen-2021-056922.
9
Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial.伴有emicizumab预防治疗的 A 型血友病患者同时使用的因子 VIII 浓缩物凝血潜能评估的研究方案（CAGUYAMA 研究）：一项多中心开放标签非随机临床试验。
BMJ Open. 2023 Jul 10;13(7):e072565. doi: 10.1136/bmjopen-2023-072565.
10
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.每4周给予艾美赛珠单抗预防治疗A型血友病患者的疗效、安全性及药代动力学（HAVEN 4）：一项多中心、开放标签、非随机3期研究
Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16.

本文引用的文献

1
Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors.在有和没有 FVIII 抑制剂的情况下，emicizumab 预防治疗用于儿科重度 A 型血友病患者的耐受性和安全性的真实世界经验。
Haemophilia. 2021 Nov;27(6):e698-e703. doi: 10.1111/hae.14432. Epub 2021 Oct 10.
2
Low immunogenicity of emicizumab in persons with haemophilia A.艾美赛珠单抗在血友病 A 患者中的免疫原性较低。
Haemophilia. 2021 Nov;27(6):984-992. doi: 10.1111/hae.14398. Epub 2021 Sep 4.
3
Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.
对血友病 A 患者血浆样本进行抗emicizumab 抗体降低药物疗效的详细分析。
J Thromb Haemost. 2021 Dec;19(12):2938-2946. doi: 10.1111/jth.15506. Epub 2021 Sep 28.
4
Non-inhibitory antibodies inducing increased emicizumab clearance in a severe haemophilia A inhibitor patient.在一名重度甲型血友病抑制剂患者中诱导emicizumab清除率增加的非抑制性抗体。
Haematologica. 2021 Aug 1;106(8):2287-2290. doi: 10.3324/haematol.2021.278579.
5
Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor.对一名患有A型血友病且产生抑制剂的患者体内中和性抗emicizumab抗体的特征分析。
J Thromb Haemost. 2021 Mar;19(3):711-718. doi: 10.1111/jth.15226. Epub 2021 Feb 1.
6
Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A.长达 5.8 年的依库珠单抗的长期安全性和疗效以及患者对症状和日常生活的认知：一项严重 A 型血友病患者的 1/2 期研究。
Haemophilia. 2021 Jan;27(1):81-89. doi: 10.1111/hae.14205. Epub 2020 Nov 24.
7
Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation.患有抑制物的重度血友病 A 患者的emicizumab 中和抗体：新病例及详细的实验室评估。
J Thromb Haemost. 2020 Sep;18(9):2205-2208. doi: 10.1111/jth.14957. Epub 2020 Jul 6.
8
An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.一种抗因子IXa/因子X双特异性抗体——emicizumab，可改善获得性血友病A患者血浆的体外凝血潜能。
J Thromb Haemost. 2020 Apr;18(4):825-833. doi: 10.1111/jth.14746. Epub 2020 Feb 26.
9
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.一项emicizumab 预防治疗伴抑制物的血友病 A 患儿的多中心、开放性 3 期研究。
Blood. 2019 Dec 12;134(24):2127-2138. doi: 10.1182/blood.2019001869.
10
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.一项emicizumab 每 2 或 4 周给药的多中心、开放性研究，用于患有无抑制剂的严重血友病 A 的儿童。
Haemophilia. 2019 Nov;25(6):979-987. doi: 10.1111/hae.13848. Epub 2019 Sep 12.